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Abstract
Background and aims—The natural history and the role of atherosclerotic plaque located 
behind the stent (PBS) are still poorly understood. We evaluated the serial changes in PBS 
following bare-metal (BMS) compared to first-generation drug-eluting stent (DES) implantation 
and the impact of these changes on in-stent neointimal hyperplasia (NIH).
Methods—Three-dimensional coronary reconstruction by angiography and intravascular 
ultrasound was performed after intervention and at 6–10-month follow-up in 157 patients with 188 
lesions treated with BMS (n=89) and DES (n=99).
Results—There was a significant decrease in PBS area (−7.2%; p<0.001) and vessel area 
(−1.7%; p<0.001) after BMS and a respective increase in both areas after DES implantation 
(6.1%; p<0.001 and 4.1%; p<0.001, respectively). The decrease in PBS area significantly 
predicted neointimal area at follow-up after BMS (β: 0.15; 95% confidence interval [CI]: 0.10–
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0.20, p<0.001) and DES (β: 0.09; 95% CI: 0.07–0.11; p<0.001) implantation. The decrease in PBS 
area was the most powerful predictor of significant NIH after BMS implantation (odds ratio: 1.13; 
95% CI: 1.02–1.26; p=0.02).
Conclusions—The decrease in PBS area after stent implantation is significantly associated with 
the magnitude of NIH development at follow-up. This finding raises the possibility of a 
communication between the lesion within the stent and the underlying native atherosclerotic 
plaque, and may have important implications regarding the pathobiology of in-stent restenosis and 
late/very late stent thrombosis.
Keywords
atherosclerosis; plaque; neointimal hyperplasia; neoatherosclerosis; in-stent restenosis; stent 
thrombosis
1. Introduction
The predictive power of atherosclerotic plaque located behind the stent (PBS) on subsequent 
neointimal growth and restenosis has been a focus for research over the past two decades. In 
the early era of percutaneous coronary revascularization, ample evidence showed that the 
amount of residual atherosclerotic plaque after coronary balloon angioplasty or atherectomy 
correlates with restenosis rate [1, 2]. In contrast, the role of PBS after coronary stenting 
remains controversial [3–6].
In-stent restenosis remains a major limitation of bare-metal stents (BMS). While drug-
eluting stents (DES) drastically reduce its occurrence, they do not eliminate it [7]. It mainly 
results from aggressive neointimal hyperplasia (NIH), but recent data also indicate a shift in 
the underlying pathological substrate toward restenotic lesions with a higher proportion of 
in-stent atherosclerotic plaque or neoatherosclerosis [8]. The pathogenesis of in-stent 
atherosclerosis development is poorly understood.
The present post hoc analysis of Prediction of Progression of Coronary Artery Disease and 
Clinical Outcome Using Vascular Profiling of Shear Stress and Wall Morphology 
(PREDICTION) study offers the opportunity to investigate the natural history of PBS after 
implantation of BMS compared to sirolimus-eluting (SES) and paclitaxel-eluting (PES) 
stents and provide insight into its role in neointimal formation.
2. Materials and methods
2.1. Study population
We analyzed the data of patients enrolled in the PREDICTION study [9], a prospective, 
multicenter study investigating the role of endothelial shear stress and vascular remodeling 
in the anatomic natural history of coronary atherosclerosis in patients presenting with an 
acute coronary syndrome. The patients underwent intracoronary vascular profiling with 
intravascular ultrasound (IVUS) and angiography of all major coronary arteries at the time 
of percutaneous coronary intervention. A large subset of consecutive, unselected patients 
underwent routine follow-up vascular profiling after 6–10 months to assess the anatomic 
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natural history in relation to antecedent vascular characteristics. The study was performed in 
Japanese clinical sites because patients routinely undergo follow-up catheterization after 
successful percutaneous coronary intervention for an acute coronary syndrome, and this 
clinical practice facilitated the performance of a large natural history study. The 
PREDICTION study found that new cardiac events (primarily requirement of a percutaneous 
coronary intervention for rapid progression of luminal obstruction), were correlated with a 
large plaque burden, but observed as well that local low endothelial shear stress was also an 
independent determinant of new cardiac events. The study population of the present analysis 
consisted of 157 patients with available serial (post-stenting and at 6–10-month follow-up) 
angiographic and IVUS data, who underwent BMS, SES (Cypher, Cordis, Johnson & 
Johnson, Miami Lakes, FL), or PES (Taxus, Boston Scientific Corporation, Natick, MA) 
implantation for culprit or non-culprit native de novo lesions (study flowchart in 
Supplemental Fig. 1). The selection of stents depended on the operator’s decision and local 
hospital policy. Inclusion criteria of PREDICTION study included age >18 years and 
presentation with an acute coronary syndrome requiring percutaneous coronary intervention. 
Exclusion criteria included heart failure New York Heart Association class III/IV, unstable 
clinical status, left main or 3-vessel coronary artery disease, significant coronary 
calcification precluding IVUS evaluation, renal failure such that additional contrast material 
would be contraindicated, clinically significant valvular disease, and life expectancy <12 
months. The study protocol was approved by the ethics review committees at each 
participating center and all patients signed written informed consent before enrollment.
2.2. Three-dimensional coronary artery reconstruction procedure and analysis
The vascular profiling procedure was performed to reconstruct the coronaries arteries in 
three-dimensional (3D) space [9]. In brief, the 3D anatomy of the stented coronary artery 
was reconstructed from two planes of coronary angiography and electrocardiographically 
gated IVUS images (Galaxy IVUS system with the Atlantis 40 MHz SR Pro IVUS catheter, 
Boston Scientific, Natick, MA) performed with automated pullback at 0.5 mm/sec. The 
arterial lumen and outer vessel wall (area within the external elastic membrane [EEM]) were 
reconstructed from digitized and segmented end-diastolic IVUS frames, using a semi-
automated system to trace the lumen and EEM borders. Each frame was aligned 
perpendicular to the catheter core. The boundary points of each frame were connected by 
spline curves to rebuild the luminal and outer vessel wall geometry in 3D space. In the 
stented regions, the stent borders were manually traced in digitized and segmented end-
diastolic IVUS frames and the 3D geometry of the stent was then reconstructed. The 3D 
geometry of the neointima was taken as the difference between the stent and the lumen. We 
divided the entire 3D-reconstructed stented artery into consecutive 1.5-mm segments. For 
analysis of serial anatomic changes, each arterial segment at baseline was compared with the 
identical segment at follow-up. Segments with incomplete apposition, defined as a 
separation of at least one stent strut from the intimal surface of the arterial wall, were 
excluded from analysis (193 segments). The following measurements were obtained for each 
segment: (i) lumen area, (ii) stent area, (iii) vessel (EEM) area, (iv) neointimal area (stent 
area minus lumen area), and (v) PBS (plaque plus media) area (vessel area minus stent area). 
Change (Δ) in each parameter was provided as follow-up minus baseline measurement. Due 
to the very low rate of adverse events in our low-risk population we used significant NIH 
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(defined as neointimal area >50% of stent area) as a binary anatomic outcome. 
Reproducibility and validation of IVUS measurements have been previously reported [10].
2.3. Statistical analysis
Continuous variables with normal and non-normal distribution are expressed as mean±SD 
and median and interquartile range (IQR), respectively. Categorical variables are presented 
as counts (percentages) and compared using the chi-square test. Analyses of area 
comparisons were performed on a per-segment basis. The association of continuous 
response variables with categorical variables was evaluated by implementing mixed-effects 
analysis of variance with the patient designated as random effects to account for within-
subject correlation due to the analysis of multiple segments in a single patient. Probability 
values were adjusted for multiple comparisons with the use of the Scheffé method. Linear 
mixed modeling was used to investigate the relationship between continuous response 
variables and continuous predictors. The association of binary response variable with 
baseline variables was evaluated by mixed-effects logistic regression. Factors entered into 
the univariable analysis included baseline vessel, lumen, and PBS areas and their respective 
changes from baseline to follow-up. Variables associated with anatomic outcomes on 
univariable analysis at p level <0.1 were considered for entry in the respective multivariable 
models, and non-significant variables were dropped by means of backward selection. 
Clinical variables (e.g., diabetes mellitus, statin use) were not associated with ΔPBS area 
and were, therefore, excluded from multivariable models. A value of p<0.05 was considered 
statistically significant.
3. Results
3.1. Patient and lesion characteristics
Patient characteristics are summarized in Table 1. Age, gender, and coronary risk factors 
were not different among stent groups. Moreover, comparable baseline demographic data 
indicate that the data in the present analysis are representative of the PREDICTION 
population. As shown in Table 2, the prevalence of underlying culprit lesion was higher in 
BMS than in SES and PES groups (89.9% vs. 54.4% vs. 48.4%, respectively; p<0.001). 
Stent lengths were shorter in BMS compared to SES and PES groups (19 mm [IQR: 16–26 
mm] vs. 22 mm [IQR: 17–29 mm]) vs. 21 mm [IQR: 17–28 mm], respectively; p=0.02).
3.2. Quantitative IVUS data
Tables 3 and 4 present quantitative IVUS parameters post-procedure and at follow-up 
analyzed on a per-segment basis. Segments with BMS implantation were negatively 
remodeled during follow-up (−1.7%; IQR: −10.0–6.0%; p<0.001), while DES segments 
exhibited outward remodeling (4.1%; IQR: −3.6–13.4%; p<0.001). There was a significant 
decrease in PBS area after BMS (−7.2%; IQR: −19.3–5.2%; p<0.001) and a significant 
increase after DES implantation (5.7%; IQR: −4.6–16.9% for SES and 9.0%; IQR: −9.4–
29.5% for PES; p<0.001 for both). The difference in ΔPBS area remained significant in 
BMS vs. DES irrespective of lesion type and location with the exception of lesions in left 
circumflex that did not reach statistical significance (Supplemental Fig. 2A and B). There 
was no significant difference in ΔPBS area between SES and PES (p=0.13). Moreover, 
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neointimal area increased significantly in BMS and PES groups, but not in SES 
(BMS>PES>SES; p<0.001 for all comparisons). Of note, 77.7% of SES segments had no 
NIH at follow-up. The lumen area decreased at follow-up in BMS and PES groups, but not 
in SES group (BMS>PES>SES; p<0.001 for all comparisons). Regarding the total plaque 
area (i.e., sum of PBS area plus neointimal area), we observed significant increases in all 3 
groups (BMS>SES; p<0.001, PES>SES; p<0.001, BMS=PES; p=0.42). Overall, the above 
mentioned differences in quantitative IVUS parameters were significantly different in BMS 
compared to entire DES group (Table 3). When comparing SES with PES, the area changes 
were similar except for the changes in neointimal, lumen, and total plaque areas (Table 4). 
Fig. 1A illustrates the natural history of vascular responses after stent implantation in all 
groups.
3.3. Relationship of changes in PBS area with neointimal area in BMS and DES
Multiple linear regression mixed modeling identified ΔPBS area (per mm2 decrease) as an 
independent predictor of neointimal area at follow-up after controlling for baseline vessel 
and lumen areas in BMS (β: 0.15; 95% confidence interval [CI]: 0.10–0.20; p<0.001), SES 
(β: 0.03; 95% CI: 0.02–0.04; p<0.001), and PES (β: 0.18; 95% CI: 0.12–0.24; p<0.001) 
(Supplemental Table 1). In addition, logistic mixed modeling revealed ΔPBS area (per mm2 
decrease) as the most powerful predictor of significant NIH development at follow-up in 
BMS (odds ratio [OR]: 1.13; 95% CI: 1.02–1.26; p=0.02), while it showed a trend toward 
being an independent predictor of significant NIH in PES (OR: 2.04; 95% CI: 0.91–4.57; 
p=0.08) (Supplemental Table 2). SES segments were excluded from latter analysis as no 
segment demonstrated significant NIH at follow-up. Supplemental Tables 3 and 4 present 
the changes in IVUS parameters according to PBS area changes and NIH development 
during follow-up, respectively.
4. Discussion
The main findings of this study are as follows: (i) PBS significantly decreases after BMS 
implantation, whereas it increases after DES implantation irrespective of underlying lesion 
type and location; (ii) the changes in PBS are associated with parallel constrictive peri-stent 
remodeling in BMS and expansive remodeling in DES; and (iii) the decrease in PBS area is 
significantly associated with the extent of neointimal area at follow-up after BMS and DES 
implantation. Taken together, this continuum suggests a unified mass effect and 
communication within the lesion where cells and tissue elements shift between the stent 
struts (Fig. 1B).
4.1. Role of PBS in neointimal formation
The role of intimal proliferation in restenosis after stent implantation has become the focus 
of much research. The contribution of PBS per se to the neointimal proliferative process 
following percutaneous coronary interventions is poorly understood. In the pre-stent era, 
residual atherosclerotic plaque assessed at the end of interventional procedures (e.g., balloon 
angioplasty, coronary atherectomy) appeared to be a consistent and independent predictor of 
subsequent restenosis [1]. Early evidence suggested that a positive correlation between the 
amount of residual PBS and the amount of late neointimal tissue growth also applied in the 
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context of bare-metal stenting [3]. These intriguing observations raised the possibility that 
the bulk of the intimal proliferation may be occurring at the original site of the lesion and led 
to an initial enthusiasm for plaque removal by adjunctive atherectomy before BMS 
implantation with results pointing to a reduction in the incidence of in-stent restenosis [11]. 
Nevertheless, the role of PBS remained controversial, as there were also studies reporting no 
association between post-BMS placement PBS and neointimal tissue growth [4, 12]. On the 
other hand, IVUS analyses in the DES era supported the notion that late in-stent neointimal 
proliferation is not related to the amount of residual PBS after DES implantation [5]. It was 
hypothesized that the eluted drug negates the impact of PBS on NIH. However, it has also 
been reported that post-intervention PBS was a predictor of NIH two years after DES 
placement [6].
Our results indicate that the decrease in PBS area during follow-up is an important 
determinant of the neointimal area after BMS and DES placement. There are several 
potential mechanisms by which the native plaque could affect post-stenting neointimal 
formation. The underlying atherosclerotic plaque may be a source for cells, growth factors, 
and chemoattractants contributing to neointimal lesion and restenotic process. Smooth 
muscle and inflammatory cells, mainly monocytes, are the predominant cells involved in this 
process. Conversely, the native plaque may be a physical barrier that prevents rupture of the 
internal elastic lamina caused by stent struts and, therefore, attenuate neointimal formation. 
It is plausible that these opposite effects counteract each other, leading, at least partly, to the 
disparity in IVUS findings. Compared to previous studies, we undertook a more 
comprehensive approach to examine the potential role of PBS taking into account the 
simultaneous accompanying changes in neointimal tissue and vessel area. Taken together, 
our findings support the idea that luminal dimensions after coronary stenting are determined 
by the combined effects of PBS, NIH, and remodeling forces. The decrease in PBS area after 
BMS implantation suggests that, as the underlying plaque progresses, it may expand across 
the stent struts, while the increase in PBS area after DES implantation suggests that the 
native atherosclerotic plaque continues to progress outwardly. The observed differential PBS 
changes after stent implantation provide insights into its biological effects and ultimately 
possible effect on clinical outcomes in BMS versus DES.
4.2. Vascular remodeling after stent implantation
Although BMS implantation eliminates the issue of immediate elastic recoil, it does not 
limit constrictive remodeling, as shown in our study, suggesting that the arterial wall may be 
squeezed through the stent strut interstices. In contrast, in line with our results, significantly 
increased vessel and plaque volume has been reported after DES placement [5]. Although 
the mechanism underlying positive vessel remodeling after DES and its impact on clinical 
outcome is still unclear, it has been assumed that expansive remodeling could be a reactive 
process to accommodate stent-related neointimal tissue proliferation and PBS progression to 
prevent restenosis. This may be analogous to arterial remodeling in the early atherosclerotic 
disease process, in which plaque accumulation is compensated for by an increase of total 
vessel area, and lumen area is usually not compromised until plaques are large. 
Alternatively, one could hypothesize that DES constitute a ‘barrier’ that prevents the inward 
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expansion of atherosclerotic tissue, which expands in an outward fashion leading to positive 
remodeling.
4.3. Implications for in-stent restenosis and stent thrombosis
To date, the mechanisms and characteristics of luminal narrowing after stent implantation 
have not been fully understood. The present study strongly implies that the progression of 
the underlying plaque between stent struts may contribute to neointimal formation and 
restenosis. In this context, the question is raised whether this potential atherosclerotic tissue 
shift after stent placement may also be responsible for neoatherosclerosis. This disease entity 
has been reported in both BMS and DES, but the underlying mechanisms remain unknown 
[8]. Based on our findings, we hypothesize that it may involve, at least partly, the 
progression of underlying residual atherosclerotic plaque in the native artery. In the same 
manner, PBS may progress after stent placement and might eventually rupture, thus, 
resulting in late/very late stent thrombosis. Therefore, a plausible argument can be made that 
continued atherosclerotic disease activity and progression of PBS between the stent struts 
may be the missing link between in-stent restenosis and stent thrombosis, and, thus, partly 
account for a range of causes of late stent failure. This assumption, although speculative, is 
supported by optical coherence tomography (OCT) observations that challenge the paradigm 
that in-stent restenosis and stent thrombosis are distinct pathological entities [8, 13]. 
Interestingly, in a recent study, intensive lipid lowering with statins prevented neointimal 
growth after DES implantation [14]. Our present observations should be considered 
hypothesis-generating only and require testing in future studies. Imaging data from IVUS 
and a high-resolution technique, such as OCT, can be complementary and synergistic in 
improving our understanding about the role of PBS in these processes.
4.4. Limitations
The PREDICTION study is an observational natural history study with stent selection based 
on the operator’s decision and policies in different centers. Our findings are based on 
observations in a relatively small number of patients raising the possibility of selection bias. 
The results of this study may not be applicable to patients who have developed angiographic 
restenosis, as none of the patients in the PREDICTION study had >50% diameter stenosis at 
follow-up angiography. Follow-up was limited to 6–10 months and therefore may not predict 
findings on later time points. IVUS has intrinsic limitations in its ability to accurately detect 
mild amounts of neointima. We are also limited by not having radiofrequency IVUS 
characterization of plaque composition available. Therefore, the current in vivo findings are 
limited to area comparisons among the groups and do not account for potentially different 
cellular compositions of the areas around the stent. With the caveat of not analyzing the 
occurrence of neoatherosclerosis, our findings are provocative worthy of further study. The 
relevance of our findings to the latest generation devices, such as drug-coated balloons and 
bioresorbable vascular scaffolds, remains to be determined.
4.5. Conclusions
The present analysis demonstrated differential dynamics of vascular responses following 
BMS and DES deployment. PBS decreases after BMS implantation and is associated with 
parallel constrictive remodeling, while it increases after DES implantation and is 
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accompanied by expansive remodeling. The reduction in PBS over time significantly 
correlates with the extent of NIH in both stent types. These findings raise the possibility of a 
communication between the lesion within the stent and the underlying native atherosclerotic 
plaque with potential tissue shifts across the stent struts, and may have important 
implications regarding the pathobiology of in-stent restenosis and late/very late stent 
thrombosis.
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• Atherosclerotic plaque behind the stent (PBS) changes after stent 
implantation
• PBS decreases after bare-metal (BMS) implantation, whereas it 
increases after first-generation first-generation drug-eluting stent (DES) 
implantation
• PBS area decrease is associated with an increase in neointimal area
• PBS plays a role in neointimal formation after stent implantation
• PBS may be implicated in stent restenosis and thrombosis
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Fig. 1. Vascular responses after bare-metal (BMS), sirolimus-eluting (SES), and paclitaxel-
eluting (PES) stent implantation
(A) Changes in quantitative intravascular ultrasound parameters between post-procedure 
examination and follow-up. Bars represent median and 95% confidence interval around the 
median. (B) Simplified schematic representation of the natural history of vascular responses 
after stent placement. In-stent lesion composition at follow-up consists of neointimal tissue 
(pink color) as a wound healing response to vascular injury, and fibrous tissue (yellow color) 
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and atherosclerotic tissue (red color) as a result of the communication with the underlying 
native atherosclerotic plaque across the stent struts. PBS: plaque behind the stent.
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Table 2
Lesion characteristics.
BMS
(n=89)
DES
p Value
BMS vs. DESSES
(n=68)
PES
(n=31)
Lesion type
  Culprit lesion 80 (89.9) 37 (54.4) 15 (48.4) <0.001
  Non-culprit lesion 9 (10.1) 31 (45.6) 16 (51.6)
Lesion location
  LAD 51 (57.3) 42 (61.8) 19 (61.3) 0.13
  RCA 25 (28.1) 10 (14.7) 4 (12.9)
  LCX 13 (14.6) 16 (23.5) 8 (25.8)
  Proximal lesion 47 (52.8) 32 (47.1) 14 (45.2) 0.57
  Mid/distal lesion 42 (47.2) 36 (52.9) 17 (54.8)
Stent length, mm 19 (16–26) 22 (17–29) 21 (17–28) 0.02
Data are n (%) or median and interquartile range.
BMS: bare-metal stent; DES: drug-eluting stent; LAD: left anterior descending; LCX: left circumflex; PES: paclitaxel-eluting stent; RCA: right 
coronary artery; SES: sirolimus-eluting stent.
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